



Biomarker for Non-invasive Colorectal Cancer Screening

PROTECTION

EP17382267.7

PCT/EP2018/062257

Priority Date: 2017/05/11

Owners: Servizo Galego de Saúde (SERGAS), Administración General de la Comunidad Autónoma de Euskadi, Asociación Centro de Investigación Cooperativa en Biociencias - CIC BioGUNE and Centro de Investigación Biomédica en Red (CIBER)

Inventors: Joaquin Cubiella Fernández, Juan Manuel Falcón Pérez and Luis Bujanda Fernández de Piérola.

BACKGROUND

Colorectal cancer (CRC) is the second most common cause of cancer mortality in developed countries. The detection of polyps in precancerous phases can reduce incidence and mortality by CRC by 30% and 50%, respectively. Currently, colonoscopy is the most accurate test for the early detection of CRC, but it has the disadvantage of causing a low level of adherence of patients to these risk exams because of the discomfort of the test and its preparation.

The social rejection of colonoscopy added to the low sensitivity of current non-invasive biomarkers for the early detection of colon cancer requires the identification of new non-invasive biomarkers with greater sensitivity and specificity.

In this aspect, metabolomics has opened new opportunities to identify these biomarkers, and also understand the mechanisms involved in the development of physiological and pathological processes.

ACHIEVEMENTS AND RESULTS

A metabolomic signature with a **high diagnostic accuracy** for **colorectal cancer (CRC)** and **advanced adenomas (AA)** detection has been developed. These **metabolic markers** selected are significantly differentiated between patients with normal colonoscopy and CRC or AA patient, and/or between CRC and AA. These metabolic markers can thus be used in a **non-invasive screening, diagnostic or monitoring method** identifying and classifying patient with **CRC and/or AA**.

The present invention provides a **novel method of screening** and / or diagnosing both **precancerous (advanced adenoma) and CRC** phases, based on the determination of the **level** of certain **metabolic markers** in a **stool sample** of the patient.

PURPOSES AND ADVANTAGES

Type of invention: Diagnostic Tool


A simple, low invasive test with high sensitive for both colorectal cancer and advanced precancerous lesions.

- ✓ **Non-invasive method**
- ✓ **Early diagnosis of the disease in precancerous phases**
- ✓ **Greater sensitivity and specificity than the only CRC biomarker available in the daily practice (f-hemoglobin concentration measured with a quantitative immunological test).**

Stool Sampling



Metabolite Analysis



Predictive value of biomarkers

High risk

Specificity 85%
Sensibility 87%

Low risk

CONTACT INFORMATION

Nerea Alonso Sousa

Innovation and Technology Transfer Unit

Fundación Biomédica - IIS Galicia Sur

Phone: +34 986 217 454

Email: innovacion@iisgaliciasur.es/

nerea.alonso.sousa@sergas.es

Webs: <http://www.fundacionbiomedica.org/>

<http://www.iisgaliciasur.es/>

COLLABORATION OFFER

Company interested in the license and commercialization of the product. If this offer is of your interest or you need more information about, please contact us.



Hospital Álvaro Cunqueiro
Estrada Clara Campoamor, 341
36312 Vigo, Pontevedra - SPAIN

www.fundacionbiomedica.org www.iisgaliciasur.es